Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

A minority of early breast cancer (EBC) patients treated with adjuvant or neoadjuvant chemotherapy have sufficient baseline vitamin D (vitD) level.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

The primary end point was the 6-month percentage of 25OHD serum level normalization.

What Was Measured

A minority of early breast cancer (EBC) patients treated with adjuvant or neoadjuvant chemotherapy have sufficient baseline vitamin D (vitD) level.

The subject headings attached to it are Breast Neoplasms, Dietary Supplements, Drug-Related Side Effects and Adverse Reactions, Neoplasm Staging, Quality of Life, Vitamin D and Vitamin D Deficiency.

The authors tagged it with the keywords chemotherapy and early breast cancer.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Annals of oncology : official journal of the European Society for Medical Oncology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.